Halozyme Therapeutics (HALO)
(Real Time Quote from BATS)
$53.77 USD
+1.22 (2.32%)
Updated Jul 9, 2024 02:22 PM ET
1-Strong Buy of 5 1
B Value B Growth D Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
HALO 53.77 +1.22(2.32%)
Will HALO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for HALO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HALO
Is Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think "Yes"
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term
HALO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Other News for HALO
Halozyme price target raised by $10 at Benchmark, here's why
Benchmark Co. Reaffirms Their Buy Rating on Halozyme (HALO)
Roche’s Ocrevus SC administration approved by European Commission
Halozyme: Roche's OCREVUS SC with ENHANZE receives EC approval
Halozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis